| Marc J Ranfone, AAC | |
|
743 Spring St Ne, Gainesville, GA 30501-3715 | |
| (770) 532-7179 | |
| (770) 534-1312 |
| Full Name | Marc J Ranfone |
|---|---|
| Gender | Male |
| Speciality | Anesthesiologist Assistant |
| Location | 743 Spring St Ne, Gainesville, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457787046 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | 006950 (Georgia) | Primary |
| Entity Name | Anesthesia Associates Of Gainesville, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457456485 PECOS PAC ID: 2769381771 Enrollment ID: O20040108000009 |
News Archive
ZIOPHARM Oncology, Inc. today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as the sole book-running manager for this offering. The co-manager for this offering is JMP Securities LLC. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The idea of fighting infections and even cancers by inducing protective immune responses may now be a step closer to clinical practice. Researchers have removed a major obstacle to widespread use of so-called adoptive transfer therapy, in which a patient receives "killer" immune cells targeting a disease agent. Existing technologies can easily provide T cells that will recognize a specific antigen, but it has been challenging to identify individual cells most likely to succeed in fighting the disease - until now.
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
When the body detects a pathogen, such as bacteria or viruses, it mounts an immune system response to fight this invader. In some people, the immune system overreacts, resulting in an overactive immune response that causes the body to injure itself, which may prove fatal in some cases.
› Verified 6 days ago
| Entity Name | Ambulatory Anesthesia Of North Georgia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497870562 PECOS PAC ID: 9931121332 Enrollment ID: O20051229000181 |
News Archive
ZIOPHARM Oncology, Inc. today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as the sole book-running manager for this offering. The co-manager for this offering is JMP Securities LLC. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The idea of fighting infections and even cancers by inducing protective immune responses may now be a step closer to clinical practice. Researchers have removed a major obstacle to widespread use of so-called adoptive transfer therapy, in which a patient receives "killer" immune cells targeting a disease agent. Existing technologies can easily provide T cells that will recognize a specific antigen, but it has been challenging to identify individual cells most likely to succeed in fighting the disease - until now.
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
When the body detects a pathogen, such as bacteria or viruses, it mounts an immune system response to fight this invader. In some people, the immune system overreacts, resulting in an overactive immune response that causes the body to injure itself, which may prove fatal in some cases.
› Verified 6 days ago
| Entity Name | North Atlanta Anesthesia Professionals, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982349296 PECOS PAC ID: 5496134348 Enrollment ID: O20220623000371 |
News Archive
ZIOPHARM Oncology, Inc. today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as the sole book-running manager for this offering. The co-manager for this offering is JMP Securities LLC. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The idea of fighting infections and even cancers by inducing protective immune responses may now be a step closer to clinical practice. Researchers have removed a major obstacle to widespread use of so-called adoptive transfer therapy, in which a patient receives "killer" immune cells targeting a disease agent. Existing technologies can easily provide T cells that will recognize a specific antigen, but it has been challenging to identify individual cells most likely to succeed in fighting the disease - until now.
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
When the body detects a pathogen, such as bacteria or viruses, it mounts an immune system response to fight this invader. In some people, the immune system overreacts, resulting in an overactive immune response that causes the body to injure itself, which may prove fatal in some cases.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marc J Ranfone, AAC Po Box 1076, Gainesville, GA 30503-1076 Ph: (770) 532-7179 | Marc J Ranfone, AAC 743 Spring St Ne, Gainesville, GA 30501-3715 Ph: (770) 532-7179 |
News Archive
ZIOPHARM Oncology, Inc. today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as the sole book-running manager for this offering. The co-manager for this offering is JMP Securities LLC. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The idea of fighting infections and even cancers by inducing protective immune responses may now be a step closer to clinical practice. Researchers have removed a major obstacle to widespread use of so-called adoptive transfer therapy, in which a patient receives "killer" immune cells targeting a disease agent. Existing technologies can easily provide T cells that will recognize a specific antigen, but it has been challenging to identify individual cells most likely to succeed in fighting the disease - until now.
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
When the body detects a pathogen, such as bacteria or viruses, it mounts an immune system response to fight this invader. In some people, the immune system overreacts, resulting in an overactive immune response that causes the body to injure itself, which may prove fatal in some cases.
› Verified 6 days ago
Amelia Jo Wiggins, CAA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-532-7179 | |
Haley Gibson, CAA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-532-7179 | |
Andrew Bryant, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-532-7179 | |
Kaitlin Schieman, AAC Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-532-7179 Fax: 770-532-7179 | |
John Tavis Mclean, AAC Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-532-7179 Fax: 770-534-1312 | |
Jeffrey Walker, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-532-7179 Fax: 770-534-1312 | |
Jesson Bateman, AAC Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-532-7179 Fax: 770-534-1312 |